Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9173847 | SALIX | Tablet comprising a fibrate |
Oct, 2024
(1 year, 6 months from now) | |
US8481078 | SALIX | Solid dosage form comprising a fibrate |
Oct, 2024
(1 year, 6 months from now) | |
US8124125 | SALIX | Solid dosage form comprising a fibrate |
Oct, 2024
(1 year, 6 months from now) | |
US7658944 | SALIX | Solid dosage form comprising a fibrate |
Dec, 2024
(1 year, 8 months from now) |
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 10 August, 2007
Treatment: Use of fenofibrate for reducing elevated total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides; For reducing total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total tri...
Dosage: TABLET;ORAL
14
United States
13
Denmark
5
European Union
4
Canada
3
Korea, Republic of
2
Japan
2
Australia
2
China
1
Hong Kong
1
Russia
1
Brazil
1
Mexico
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11529368 | SALIX | Colonoscopy—preparation |
Mar, 2032
(8 years from now) | |
US10792306 | SALIX | Colonoscopy—preparation |
Mar, 2032
(8 years from now) | |
US10780112 | SALIX | Colonoscopy-preparation |
Mar, 2032
(8 years from now) | |
US10646512 | SALIX | Colonoscopy - preparation |
Mar, 2032
(9 years from now) | |
US9592252 | SALIX | Colonoscopy—preparation |
Aug, 2032
(9 years from now) | |
US8999313 | SALIX | Compositions |
Sep, 2033
(10 years from now) | |
US10918723 | SALIX | Colon cleansing compositions and methods of use |
Sep, 2033
(10 years from now) | |
US10016504 | SALIX | Compositions |
Sep, 2033
(10 years from now) | |
US9707297 | SALIX | Compositions |
Sep, 2033
(10 years from now) | |
US9326969 | SALIX | Compositions |
Sep, 2033
(10 years from now) |
Market Authorisation Date: 04 May, 2018
Treatment: For cleansing of the colon in preparation for colonoscopy in adults
Dosage: FOR SOLUTION;ORAL
17
United States
8
European Union
7
Korea, Republic of
6
Israel
6
South Africa
6
Australia
6
Singapore
6
Spain
6
China
6
Japan
5
Denmark
5
Portugal
5
United Kingdom
4
Poland
4
EA
4
Canada
3
Mexico
3
Slovenia
3
Lithuania
3
Hungary
3
Croatia
3
Brazil
3
Malaysia
3
Taiwan, Province of China
3
RS
3
Ukraine
3
New Zealand
2
Hong Kong
2
Argentina
2
ME
1
Ireland
1
Finland
1
Cyprus
1
Netherlands
1
San Marino
1
India
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8420663 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(6 years from now) | |
US9492445 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(6 years from now) | |
US9180125 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(6 years from now) | |
US9724343 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(6 years from now) | |
US8956651 | SALIX | Oral formulations and lipophilic salts of methylnal trexone |
Mar, 2031
(7 years from now) | |
US10376505 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(7 years from now) | |
US9314461 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(7 years from now) | |
US10307417 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(7 years from now) | |
US8524276 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(7 years from now) |
Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient
Market Authorisation Date: 19 July, 2016
Treatment: Treatment of opioid-induced constipation
Dosage: TABLET;ORAL
21
United States
9
Japan
7
New Zealand
6
European Union
5
China
4
Singapore
4
Korea, Republic of
3
Israel
3
Mexico
3
Brazil
3
Poland
2
Australia
2
Hong Kong
2
Russia
2
Argentina
2
Spain
2
Taiwan, Province of China
2
Ukraine
2
Canada
1
South Africa
1
Morocco
1
Hungary
1
Costa Rica
1
Colombia
1
Portugal
1
Guatemala
1
Malaysia
1
Peru
1
Chile
1
Ecuador
1
Georgia
1
EA
1
Tunisia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7799897 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jun, 2022
(9 months ago) | |
US7041786 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jan, 2028
(4 years from now) | |
US10011637 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8637451 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Mar, 2022
(11 months ago) | |
US9925231 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(8 years from now) | |
US9919024 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(8 years from now) | |
US9610321 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(8 years from now) | |
US11319346 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Mar, 2032
(8 years from now) | |
US9616097 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Aug, 2032
(9 years from now) | |
US11142549 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 19, 2022 |
Drugs and Companies using PLECANATIDE ingredient
NCE-1 date: 2021-01-19
Market Authorisation Date: 19 January, 2017
Treatment: Elevation of intracellular cgmp resulting in increased intestinal fluid and accelerated transit; Irritable bowel syndrome with constipation; Chronic idiopathic constipation
Dosage: TABLET;ORAL
36
United States
9
Japan
8
Australia
8
European Union
7
China
6
Canada
5
Hong Kong
4
Spain
3
EA
1
Israel
1
Germany
1
Brazil
1
Portugal
1
Denmark
1
Cyprus
1
Korea, Republic of
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10660858 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(8 years from now) | |
US8895064 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(8 years from now) | |
US9192581 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(8 years from now) | |
US10307375 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(8 years from now) | |
US9132093 | SALIX | Controlled release and taste making oral pharmaceutical composition |
Sep, 2031
(8 years from now) |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 14 January, 2013
Treatment: Induction of remission in patients with active, mild to moderate ulcerative colitis
Dosage: TABLET, EXTENDED RELEASE;ORAL
34
United States
3
Japan
2
Italy
2
European Union
1
Germany
1
Hong Kong
1
Russia
1
Portugal
1
Denmark
1
Austria
1
Turkey
1
Mexico
1
Spain
1
Canada
1
Norway
1
Australia
1
China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic